Post Resch Tallon Group Inc. Cardiff Oncology, Inc. Transaction History
Post Resch Tallon Group Inc.
- $113 Billion
- Q3 2025
A detailed history of Post Resch Tallon Group Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Post Resch Tallon Group Inc. holds 22,538 shares of CRDF stock, worth $48,456. This represents 0.04% of its overall portfolio holdings.
Number of Shares
22,538Holding current value
$48,456% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
124Shares Held
21.8MCall Options Held
1.11MPut Options Held
150K-
Vanguard Group Inc Valley Forge, PA3.59MShares$7.72 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$5.65 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY2.47MShares$5.3 Million0.09% of portfolio
-
Blair William & CO Chicago, IL2.21MShares$4.76 Million0.01% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.96MShares$4.22 Million2.05% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $93.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...